The Estée Lauder Companies Unites the World in Hope With Its 2019 Breast Cancer Campaign
1.10.2019 15:30:00 EEST | Business Wire | Press release
Every 15 seconds, somewhere in the world, a woman is diagnosed with breast cancer.1 That’s why, since 1992, The Estée Lauder Companies has been committed to saving lives - uniting and positively impacting people everywhere in its Breast Cancer Campaign’s mission to create a breast cancer-free world. For 27 years, The Estée Lauder Companies has inspired action, funding the world’s leading research to bring us closer to a cure and bringing a global level of awareness to the disease. It’s #TimeToEndBreastCancer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191001005402/en/
(Photo: Business Wire)
The Estée Lauder Companies has been a leader in the global breast cancer movement since Evelyn H. Lauder co-created the Pink Ribbon and started The Breast Cancer Campaign (The Campaign) in 1992. A year later, in 1993, she founded the Breast Cancer Research Foundation® (BCRF), the highest-rated nonprofit breast cancer organization in the U.S., dedicated to advancing the world’s most promising research to eradicate breast cancer. The Campaign has raised more than $79 million to support global research, education and medical services through the collective support of consumers, employees and partners worldwide, with more than $65 million funding 260 medical research grants through BCRF. This year The Campaign aims to raise another $9 million globally.
Real impact has been made and The Campaign is proudly part of that equation. Mortality rates from breast cancer have declined by 40% among women since the late 1980’s2 and BCRF-funded researchers have been involved in every major breakthrough in breast cancer prevention, diagnosis, treatment and survivorship. Breast cancer is spoken about more openly and important messages about early detection are saving lives – five-year survival rates are better than 90% with early detection.3
William P. Lauder, Executive Chairman of The Estée Lauder Companies Inc., proudly champions The Campaign’s mission and continues to honor the legacy of his late mother, stating, “The Breast Cancer Campaign is an expression of the best of what we do as a company. My mother, Evelyn Lauder, had a vision to end breast cancer when she started The Campaign in 1992. Since then, we have been pioneers in the breast cancer movement, driven by our passionate employees, partners and consumers around the world. I am so proud that her legacy lives on as we remain committed to making sustainable investments in research, education and medical services to bring us closer to eradicating this disease.”
The Estée Lauder Companies’ commitment to support research, and all of those touched by breast cancer, remains unwavering. Breast cancer is the most common cancer in women worldwide and is increasing particularly in developing countries where the majority of cases are diagnosed in late stages.4 It is the second most common cancer overall.5 Men are also touched by the disease - their lifetime risk of getting breast cancer is about 1 in 833.6
The Campaign will continue to drive worldwide efforts aligned to its mission:
-
Launch a new social media call to action to rally supporters around the world to participate and raise funds through the simple action of drawing a Pink Ribbon on the back of their hand using pink lipstick, sharing why it’s #TimeToEndBreastCancer and posting a photo on Instagram, also with #ELCdonates
- For every public, in-feed Instagram post during the month of October featuring both #TimeToEndBreastCancer and #ELCdonates together, @esteelaudercompanies will donate $25 (a half hour of research) up to $250,000 to @bcrfcure. $250,000 will fund a one-year BCRF research grant.
- Illuminate buildings, monuments and landmarks worldwide in glowing pink lights to raise awareness of breast health– including the Empire State Building, New York City, the Eiffel Tower, Paris, and Kiyomizu-dera Temple, Kyoto
- Distribute informational brochures and pink ribbons at The Estée Lauder Companies’ beauty brand counters worldwide
- Mobilize 48,000 employees to positively impact communities and unite in action
- Drive donations to BCRF through ELCompanies.com/BreastCancerCampaign
Elizabeth Hurley, The Campaign’s longtime Global Ambassador shared, “I am honored to represent The Breast Cancer Campaign and help bring attention to the powerful work The Estée Lauder Companies does each year to unify and activate the global community around the cause. Every time someone shares with me that they got a mammogram because they heard our messages, or unfortunately tells me that they have been diagnosed with breast cancer, I’m reminded of why we must continue Evelyn’s mission. I’ve seen research we are funding in action, spoken to many leaders in the field and know how hopeful they all remain – we are making real progress towards a cure and must continue to fund that advancement!”
“The Estée Lauder Companies has long been committed to making an impact on communities around the world, and our efforts through The Breast Cancer Campaign are a reflection of that purpose and underscore the Company’s family values and culture. We will continue to strive towards fulfilling the mission of The Campaign to create a breast cancer-free world,” said Fabrizio Freda, President and Chief Executive Officer, The Estée Lauder Companies Inc.
This year, 19 of the The Estée Lauder Companies’ beauty brands will support The Campaign's mission: AERIN, Aveda, BECCA, Bobbi Brown, Bumble and bumble, Clinique, Darphin, DKNY, Donna Karan, Estée Lauder, GLAMGLOW, Jo Malone London, La Mer, Lab Series, Origins, Prescriptives, RODIN olio lusso, Smashbox, and Tom Ford Beauty. Each will contribute by selling Pink Ribbon Products or making donations to BCRF and/or other charitable organizations around the world. The assortment differs by country and organization.
The Campaign is a true testament to who we are as a company, the dedication of our people, our family values and most importantly the lives we can have a positive impact on around the world through our efforts as global citizens. It’s #TimeToEndBreastCancer.
To learn more about The Estée Lauder Companies’ Breast Cancer Campaign, visit ELCompanies.com/BreastCancerCampaign
ABOUT THE ESTÉE LAUDER COMPANIES INC.
The Estée Lauder Companies Inc. is one of the world’s leading manufacturers and marketers of quality skin care, makeup, fragrance and hair care products. The Company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Prescriptives, Lab Series, Origins, Tommy Hilfiger, M·A·C, Kiton, La Mer, Bobbi Brown, Donna Karan New York, DKNY, Aveda, Jo Malone London, Bumble and bumble, Michael Kors, Darphin, Tom Ford, Smashbox, Ermenegildo Zegna, AERIN, Tory Burch, RODIN olio lusso, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, By Kilian, BECCA and Too Faced.
ELC-C
ELC-I
- Source: GLOBOCAN 2018 Breast Cancer Report, International Agency for Research on Cancer (http://gco.iarc.fr/today/data/factsheets/cancers/20-Breast-fact-sheet.pdf)
- Source: American Cancer Society, 2019 Trends in Breast Cancer Deaths (cancer.org/cancer/breast-cancer/about/how-common-is-breast-cancer.html)
- Source: American Cancer Society, 2019 Survival Rates for Breast Cancer (https://www.cancer.org/cancer/breast-cancer/understanding-a-breast-cancer-diagnosis/breast-cancer-survival-rates.html)
- Source: World Health Organization 2019, Breast Cancer: Prevention and Control (https://www.who.int/cancer/detection/breastcancer/en/index1.html)
- Source: GLOBOCAN 2018 Report via World Cancer Research Fund, Breast Cancer Statistics (https://www.wcrf.org/dietandcancer/cancer-trends/breast-cancer-statistics)
- Source: American Cancer Society 2019 Key Statistics for Breast Cancer in Men (https://www.cancer.org/cancer/breast-cancer-in-men/about/key-statistics.html)
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191001005402/en/
Contact information
Bari Seiden-Young
The Estée Lauder Companies
212-572-4475
bseiden@estee.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Global Tech Sales Forecast to Reach $1.4 Trillion in 2026, Even as 56% of Consumers Delay Purchases, NIQ Finds1.9.2026 10:00:00 EEST | Press release
Global sales of consumer technology and durable goods are forecast to reach $1.4 trillion in 2026, up 5.1% year over year, even as 56% of consumers say they have delayed a technology purchase because of price or while waiting for a discount, according to new research from NIQ (NYSE: NIQ), the Official Global Insights Partner of IFA. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260901758503/en/ The era of automatic tech & durables upgrades is over. Released ahead of IFA 2026, which kicks off in Berlin on Sept. 4, 2026, NIQ today released its annual “State of Tech & Durables” report. Consumer Tech Trends 2027: How to Win When Every Purchase Must Be Justified examines how years of economic volatility have transformed technology purchasing behavior and what manufacturers and retailers must do to remain competitive. Key findings include: Global T&D sales are forecast to reach $1.4 trillion in 2026, up 5.1% year over year 63% of
Searchlight Capital Partners Announces Investment in Aderian Group1.9.2026 10:00:00 EEST | Press release
Searchlight Capital Partners, L.P. ("Searchlight"), a leading global private investment firm, today announced an investment in Aderian Group ("Aderian" or the "Company"), a Nordic managed IT services provider serving more than 10,000 small and medium-sized enterprise ("SME") customers throughout Sweden and Norway. As part of the transaction, Aderian's management team will reinvest in the Company and remain meaningful shareholders alongside Searchlight, underscoring their continued commitment to Aderian's long-term growth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260901430715/en/ Aderian provides cloud, cybersecurity, AI and analytics, networking and modern workplace solutions. Since its founding in 2022, the Company has grown to approximately SEK 2.5 billion in revenue, with more than 850 employees and over 10,000 SME customers across Sweden and Norway. The Company has built deep, long-standing customer relationships b
FluoSphera Licenses Debiopharm’s AbYlink™ Technology for 3D Antibody Characterization while Leveraging Leica Microsystems Viventis Deep Imaging Capabilities1.9.2026 10:00:00 EEST | Press release
Debiopharm (Debiopharm Research & Manufacturing), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard of care to cure cancer and infectious diseases and FluoSphera, a Swiss biotechnology company developing advanced in vitro platforms to improve the prediction of drug efficacy and safety, today announced a new license agreement for use of AbYlink™, Debiopharm’s proprietary antibody conjugation technology. The agreement enables FluoSphera to offer biotechnology and pharmaceutical companies an integrated workflow combining regio-selective antibody labeling, high-throughput testing in human-relevant three-dimensional models and quantitative imaging analysis. The new offering is designed to support the characterization of antibody-drug conjugates (ADCs), bispecific antibodies, therapeutic antibodies and other antibody-based modalities. Antibody candidates can be labeled using AbYlink™ and subsequently be evaluated with FluoSphera’s 3D testing pla
Enhertu ® Plus Pertuzumab Approved in the EU as First New Regimen in More than a Decade for First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer1.9.2026 09:30:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) in combination with pertuzumab has been approved in the European Union (EU) for the first-line treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from theDESTINY-Breast09 phase 3 trialpresented at the 2025 American Society of Clinical Oncology Annual Meeting and subsequently published in The New England Journal of Medicine. In DESTINY-Breast09, Enhertu in combination with pertuzumab reduced the risk of disease progression or death by 44% versus a taxan
Paris Hilton Returns as the Face of KARL LAGERFELD as NOT-KARL Debuts for Fall–Winter 20261.9.2026 09:30:00 EEST | Press release
Following the success of the Maison's Fall-Winter 2025 and Spring-Summer 2026 campaigns, KARL LAGERFELD is delighted to announce the extension of its relationship with global entrepreneur, media personality and cultural icon Paris Hilton, continuing a partnership that has resonated with audiences around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831566835/en/ KARL LAGERFELD - Paris Hilton ©Matt Easton As the face of the Maison through Fall-Winter 2026 and Spring-Summer 2027, Paris Hilton returns for the next chapter of KARL LAGERFELD's From Paris With Love story, continuing to bring her signature confidence, wit and individuality. Photographed for the first time by Matt Easton, the Fall-Winter 2026 campaign introduces a new dimension to the narrative while remaining true to the House's established codes. At the heart of the Fall-Winter 2026 story, two masters of self-reinvention meet. Making his debut is NO
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
